TOKYO, Jan 26, 2023 - (JCN Newswire via SEAPRWire.com) - Nippon Steel Corporation, Mitsubishi Corporation and ExxonMobil Asia Pacific Pte. Ltd. have signed a Memorandum of Understanding to jointly study carbon capture and storage (CCS) and the establishment of potential CCS value chains in the Asia Pacific regions on January 25, 2023. Based on the Memorandum, the three companies will conduct research on the capture of CO2 emissions from Nippon Steel's domestic steelworks and evaluate the necessary infrastructure development required, with a view to establishing CCS value chains in the Asia-Pacific region. It would also include a detailed evaluation of Asia Pacific storage opportunities, including in Malaysia, Indonesia and Australia. Mitsubishi Corporation plans to evaluate the overseas CO2 transportation and the development of CCS value chain. This is the first study to develop value chains for carbon capture in Japan with the aim to store elsewhere overseas in the region. Nippon Steel set forth the "Nippon Steel Carbon Neutral Vision 2050" in its medium- to long-term management plan announced in March 2021 and positioned CCS as one of the key technologies to realize this vision. Through this study, Nippon Steel will progress the implementation of CCS including securing storage sites for overseas storage of CO2 generated from steel works, developing storage infrastructure, advocating for policies and regulation, and examining its cost adequacy. Mitsubishi Corporation has identified Energy Transformation (EX) as a key initiative in its Roadmap for a Carbon Neutral Society formulated in October 2021 and its Medium-Term Management Strategy 2024 released in May last year. Mitsubishi Corporation will evaluate the overseas CO2 transportation and the development of CCS value chain through this joint effort. ExxonMobil continues to advance innovative solutions for a lower-carbon future. In early 2021, it established a Low Carbon Solutions business, which is working to bring lower-emission technologies to market, making them accessible to hard-to-decarbonize industries. It is committed to accelerating significant emission reductions through strategic collaborations and through leading the development and the deployment of scalable lower-emission technologies, such as CCS, needed to advance solutions for various industries in the Asia Pacific region and beyond. Mitsubishi Corporation will continue to lead EX through the low-carbon and decarbonization of our business through CCS and other initiatives, while contributing to the transition and realization of a carbon-neutral society through the stable supply of cleaner energy. About Nippon Steel CorporationNippon Steel Corporation is Japan's largest and one of the world's leading integrated steel producers with a wide range of value-added steel products in more than 15 countries. Nippon Steel has four business segments: steelmaking and steel fabrication, engineering and construction, chemicals and materials, and system solutions. With the aim of continually growing to become "the best steelmaker with world-leading capabilities" from the present and into the future, Nippon Steel will pursue world-leading technologies and manufacturing capabilities, and contribute to society by providing excellent products and services. For more information about Nippon Steel please visit: www.nipponsteel.com/ About Mitsubishi CorporationMitsubishi Corporation works with its roughly 1,700 subsidiaries, affiliates and group companies to develop businesses in approximately 90 countries around the world. Spanning multiple industries and regions, these businesses are overseen by Mitsubishi Corporation's Industry DX Group and 10 Business Groups: Natural Gas, Industrial Materials, Petroleum & Chemicals, Mineral Resources, Industrial Infrastructure, Automotive & Mobility, Food Industry, Consumer Industry, Power Solution, and Urban Development. Through joint digital (DX) and energy (EX) transformations invested in sustainability, decarbonization and digitalization, the company is now focused on leveraging its operations to address myriad challenges that stand to impact our planet's future. About ExxonMobilExxonMobil, one of the largest publicly traded international energy and petrochemical companies, creates solutions that improve quality of life and meet society's evolving needs. The corporation's primary businesses - Upstream, Product Solutions and Low Carbon Solutions - provide products that enable modern life, including energy, chemicals, lubricants, and lower-emissions technologies. ExxonMobil holds an industry-leading portfolio of resources, and is one of the largest integrated fuels, lubricants and chemical companies in the world.The Singapore affiliate, ExxonMobil Asia Pacific Pte. Ltd., has manufacturing facilities which include an integrated world-scale refining and petrochemical complex in Jurong and Jurong Island. Our operations and businesses serve customers and commercial markets in the region with ground transportation, industrial, aviation and marine fuels, lubricants, petrochemicals and liquefied natural gas. To learn more, visit exxonmobil.com and the Energy Factor. Follow us on Twitter and LinkedIn. For further information, contact:Nippon Steel Corporation, Public Relations Center Tel: 03-6867-2977Mitsubishi Corporation, Press Relations Team, Corporate Communications Dept. Tel: 03-3210-2171 Fax: 03-5252-7705ExxonMobil Asia Pacific Pte. Ltd: +65 6885 2389 Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)
SYDNEY, AU, Dec 20, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023. Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.Meetings can be scheduled via the PartneringOne portal. https://informaconnect.com/biotech-showcase/partnering/Novotech will share the Asia Pacific advantages for expedited clinical trials, where biotechs have access to Novotech's vast patient populations, strong local regulatory knowledge, extensive site and KOL networks, and reputation for data quality.Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific. According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific. The data shows almost 12,900 of the new trials had sites in Asia Pacific.Download the report here https://novotech-cro.com/whitepapers/state-global-biotech-landscape-where-opportunities-lieThe report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region. Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. About Novotech - https://novotech-cro.comNovotech is internationally recognized as the leading Asia Pacific centred contract research organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
TOKYO, Dec 16, 2022 - (JCN Newswire via SEAPRWire.com) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, announced that it has been selected for inclusion in the 2022 Dow Jones Sustainability World Index (DJSI World) and the 2022 Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), both among the most globally recognized corporate sustainability indices. Olympus has been named to the DJSI World for two consecutive years and DJSI Asia Pacific for four.The Dow Jones Sustainability Indices (DJSI) are corporate sustainability evaluation indices for environmental, social, and governance (ESG) investment. Jointly developed by S&P Dow Jones Indices and RobecoSAM, the DJSI track the financial performances of leading companies according to ESG criteria. These indices are updated annually to include companies with excellent corporate sustainability practices.In 2022, 332 companies were selected as DJSI World members from approximately 3,500 companies worldwide in 61 industry sectors, and 156 companies were selected as DJSI Asia Pacific members from approximately 600 companies assessed in the region. Olympus is one of only 8 out of 64 companies to have been included in the DJSI World Health Care Equipment & Supplies sector. The company's scores on Access to Healthcare, Talent Attraction & Retention, Tax Strategy, Environmental Policy & Management Systems were of particular note, being not only highly rated, but having also been improved over last year's scores. In addition to the DJSI World and Asia Pacific, Olympus was also named to the FTSE4Good Index Series and FTSE Blossom Japan Index.Stefan Kaufmann; Director, Executive Officer, and Chief Administrative Officer of Olympus, stated: "It is a great honor for Olympus to again be selected for the DJSI World and Asia Pacific. In order to realize Our Purpose of Making people's lives healthier, safer and more fulfilling, we have taken various initiatives to contribute to society, positioning ESG as one of the most important strategic pillars in our Corporate Strategy. We are proud to be included in the DJSI World and Asia Pacific for consecutive years as evidence of our continuous evolution as well as our high reputation in ESG from stakeholders. We will further accelerate our efforts to realize a sustainable society."Based on Our Purpose, Olympus believes that the sustainability of a company will be recognized primarily by meeting the demands and expectations of society and fulfilling responsibilities through dialogue with all stakeholders. The company will continue to contribute to creating a sustainable society by actively engaging in activities that incorporate ESG perspectives to fulfill its corporate social responsibilities on a global scale.For more information on Olympus' ESG initiatives, please refer to its Integrated Report 2022[1] and the Sustainability page on its website[2].[1] https://www.olympus-global.com/ir/data/integratedreport/2022.html?page=ir[2] https://www.olympus-global.com/csr/About OlympusOlympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people's lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 30,000 employees worldwide in nearly 40 countries and regions. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp ( https://twitter.com/olympus_corp ).Media contact:Mieko YamadaGlobal-Public_Relations@olympus.comOlympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLYS] https://www.olympus-global.com Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
SYDNEY, AU, Dec 15, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific. The data shows almost 12,900 of the new trials had sites in Asia Pacific.Download the report here https://novotech-cro.com/whitepapers/state-global-biotech-landscape-where-opportunities-lieThe report also noted that the Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region. In addition, analysis of trial growth trends found that Asia Pacific has also seen high phase-level growth over the 5-year analysis period to 2022.- Phases I and II were dominated by Asia Pacific, which served as a trial location in 57% and 49% of trials, respectively.- US and EU remained stable at approximately 20% at phases I through III.- RoW representation is low in phases I and II but on par with the US and EU in phase III.Novotech this month was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006. Frost & Sullivan identifies companies that consistently develop growth strategies based on a visionary understanding of the future, and effectively address new challenges and opportunities. Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."In response to the Company of the Year Award announcement, Novotech CEO Dr. John Moller said this award is a credit to our entire global team which has decades of biotech drug development experience. "Our global clients benefit from access to our expert teams in Asia Pacific, which is the fastest-growing clinical trial region, due to its vast patient populations and sophisticated medical research infrastructure. Our consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution."Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech provides the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions delivering exclusive benefits for sponsors.About Novotech - https://novotech-cro.comNovotech is internationally recognized as the leading Asia Pacific centred contract research organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies. For more information visit https://novotech-cro.com/contactMedia ContactDavid Jamescommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
SYDNEY, AU, Dec 6, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.Frost & Sullivan identifies companies that consistently develop growth strategies based on a visionary understanding of the future, and effectively address new challenges and opportunities.Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognizes Novotech for its valuable achievement. Novotech addresses the global drug development market's unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients."In response to the Company of the Year Award announcement, Novotech CEO Dr. John Moller said this award is a credit to our entire global team which has decades of biotech drug development experience."Every day our team supports biotech companies in their drug development programs with unparalleled regulatory knowledge, vast site and investigator networks, technology-driven clinical data management, and a project management approach focused on problem-solving, ownership, and flexibility. Our global clients benefit from access to our expert teams in Asia Pacific, which is the fastest-growing clinical trial region, due to its vast patient populations and sophisticated medical research infrastructure. Our consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution."Novotech regularly produces expert reports on East-West strategies. A new publication is now available for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Novotech can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA approval process, avoiding delays and additional costs.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech has also recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions delivering exclusive benefits for sponsors.About Novotech Novotech is the leading Asia Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
JAKARTA, Oct 24, 2022 - (ACN Newswire via SEAPRWire.com) - The 'High-level Intergovernmental Meeting on the Final Review of the Asian and Pacific Decade of Persons with Disabilities' (HLIGM APDPD) closed on Friday (Oct 21) with 53 Asia-Pacific and 9 associated countries adopting the landmark Jakarta Declaration, marking the start of the fourth 'Asian and Pacific Decade of Persons with Disabilities'.53 Asia-Pacific and 9 associated UN ESCAP countries adopted the Jakarta Declaration 2023-2032, October 21, 2022. (ANTARA/Ministry of Social Affairs)Participants in the Meeting on the Final Review of the Asian and Pacific Decade of Persons with Disabilities 2013-2023, Oct 21, 2022. (ANTARA/Ministry of Social Affairs)"Today, on the last day of the high-level intragovernmental meeting in the Asia Pacific, we are adopting the Jakarta Declaration 2023-2032, which will be followed up by all members, accelerated and implemented," said the meeting chair and Indonesian Social Affairs Minister, Tri Rismaharini (Risma). "Through the Jakarta Declaration, we reaffirm our global commitment to a better life for all persons with disabilities," said Risma, emphasizing the commitment of Asia Pacific countries in realizing the Incheon Strategy, initiated ten years ago. "The priority issue is an alignment of the Convention on the Rights of Persons with Disabilities (CRPD) at the level of legislation.""It is time to increase efforts and take affirmative steps to implement universal design in all public areas, to increase the capacity of people handling persons living with disabilities in all sectors, and conduct national breakthrough campaigns to build awareness about disability," she said. "Harmonization of legislation is the toughest challenge for our own government, as it has central, provincial and regency/city government levels."Under-Secretary-General of the United Nations, and Executive Secretary of the Economic and Social Commission for Asia and the Pacific (UN ESCAP), Armida Salsiah Alisjahbana said although the implementation of the CRPD was making progress, people with disabilities in the Asia Pacific region face obstacles in education, work, decision making, and many other aspects.She invites UN ESCAP members to strengthen partnerships with disability organizations, the private sector, United Nations entities and the others to create a comprehensive community approach. Armida hopes that people with disabilities can participate in all policies and programs related to disability actively and significantly, in line with the spirit of 'nothing without us about us'.HLIGM APDPD was held on a hybrid basis from 19 - 21 October 2022 and was attended by delegates from 53 member states, 9 association member, observer countries, UN agencies, and civil society organizations.Written by: PR Wire, Editor: PR Wire (c) ANTARA 2022Source article at: https://en.antaranews.com/news/256377/asia-and-pacific-countries-make-jakarta-declaration-agreementUN ESCAP member countries also underlined the importance of making strategic investments to push disability-inclusive development through a whole-society approach in collaboration with relevant stakeholders, especially organizations of persons with disabilities and private sector entities, in order to accelerate action to promote and protect the rights of persons living with disabilities."I encourage all participants to continue their cooperation with one another and to take all necessary steps to make the recommendations formulated during this meeting in Jakarta. Now and in the next decade, we must come together and work it out," Rismaharini said.The first point of the Jakarta Declaration is to harmonize national legislations with the Convention on the Rights of Persons with Disabilities, after the convention is ratified, by conducting a comprehensive and regular review of national legislations and appropriate regional regulations.The second is to promote the meaningful participation of women and men with disabilities of all ages, including by closely consulting and actively involving children and youth with disabilities through their representative organizations, in planning, implementation, and decision-making on policies, programs, and political processes through reasonable accommodation.The third point involves special attention to the special needs of persons with diverse disabilities and women, children, and elderly with disabilities to increase accessibility of the physical environment, including information and communication technology and systems, public transportation, and essential information and services related to disaster risk and public health emergencies and other public services.The fourth is to promote the power of the private sector, including its resources, innovation, and technology talent, to push disability-inclusive development by adopting disability-inclusive public procurement policies to promote the adoption of universal design and accessibility measures for infrastructure, technology, and information and communication services that are publicly obtained.The fifth is to promote a gender-responsive life cycle approach to develop and implement policies and programs related to disability by paying special attention to children, youth, women, and elderly people living with disabilities.The sixth is to take action, based on information provided by competent national institutions and other recognized sources, to close the disability data gap and strengthen the capacity to track progress in disability-inclusive development at the national and subnational levels by producing comparable and qualified data as chosen by gender, age, and disability across sectors. Written by: Devi Nindy Sari R, Resinta S, Editor: Rahmad Nasution (c) ANTARA 2022Source article: https://en.antaranews.com/news/256205/53-asia-pacific-countries-agree-to-jakarta-declaration-on-disability Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
JAKARTA, Oct 23, 2022 - (ACN Newswire via SEAPRWire.com) - The High-level Intergovermental Meeting on The Final Review of The Asian and Pacific Decade of Persons with Disabilities (HLIGM APDPD) was closed with the Jakarta Declaration agreement, which marked the start of the fourth decade of Asia and Pacific Decade of Persons with Disabilities.Participants of the meeting on the final Review of the Asian and Pasific Decade of Persons with Disabilities 2013-2023 in Jakarta, Friday (October 21, 2022).(ANTARA/Ministry of Social Affairs)"Today is the last day and the high-level meeting between governments in the Asia Pacific was closed and we are making the Jakarta Declaration 2023-2032 which will be followed up by members, accelerated and implemented," said Indonesian Social Affairs Minister Tri Rismaharini in Jakarta.The Jakarta Declaration is expected to be able to reaffirm the commitment of the governments of Asia Pacific countries in realizing the Incheon Strategy, which was initiated ten years ago.The Jakarta Declaration has six resolutions. One of the priority issues is the alignment of the Convention on the Rights of Persons with Disabilities (CRPD) at the level of legislation.According to Risma, harmonization of legislation is the toughest challenge for the Indonesian government because it has three levels of government, namely, the central government, provincial government and regency/city government.Meanwhile, Under-Secretary-General United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), Armida Salsiah Alisjahbana, said although the implementation of the CRPD making progress, people with disabilities in the Asia Pacific region face obstacles in education, work, decision making, and many other aspects.Therefore he invites UNESCAP members to strengthen new partnerships with disability organizations, the private sector, United Nations entities and the others to create a comprehensive community approach.Armida hopes that people with disabilities can participate in all policies and programs related to disability actively and significantly, in line with the spirit of 'nothing without us about us'.HLIGM APDPD was held on a hybrid basis during 19 - 21 October 2022 and was attended by delegates from 53 member states, 9 association member, observer countries, UN agencies, and civil society organizations.See the original article: https://en.antaranews.com/news/256377/Written by: PR Wire, Editor: PR Wire (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
DOVER, DE, Oct 19, 2022 - (ACN Newswire via SEAPRWire.com) - Pacific Green Technologies, Inc. (the "Company" or "Pacific Green", (OTCQB:PGTK) announces that Alexander Shead has been appointed as an Independent Director, effective October 16th, 2022. Alex previously served as Executive Director for the Company from July 2016 to October 2020.Alex is Chairman of Lockton Pacific (2012-present), a subsidiary of Lockton Companies, Inc., the world's largest privately held, independent insurance brokerage firm, ranked 8th largest globally. Alex is also the Responsible Manager with the Australian Securities and Investments Commission (ASIC).In 2008, Alex conceived the award-winning Non-Governmental Organization (NGO), Food Ladder, and remains Chairman today. Food Ladder was one of the first NGOs in the world to use environmentally sustainable technologies to create food and economic security for communities affected by poverty. Alex was also the founder of Fair Repairs, a social enterprise which delivers training and employment opportunities to individuals suffering from long term unemployment and disadvantage.Alex is a British, Australian and Swiss national, educated at Harrow School in England and La Sorbonne University in Paris, France. In 1993, Alex co-founded Stuart Alexander, leading the company to become one of the UK's largest insurance and risk management advisory businesses, ultimately selling to AXA, UK.In 2004, Alex relocated to Australia where he was a shareholder and director of Milne Alexander, a boutique insurance broking and advisory firm. From 2008 to 2014, Alex was the Executive Chairman of the Mecon Winsure Insurance Group, one of Australia's leading insurance and underwriting agencies, acting as a Coverholder for Lloyd's of London and local Australian insurers. Mecon Winsure Insurance Group was sold to ASX-listed Steadfast Group Ltd. in 2014.Alex's track record of creating shareholder value through Merger and Acquisition (M&A) activity has spanned over three decades. Alex has a wide range of entrepreneurial experience and an in-depth knowledge of large-scale enterprise acquisition and operational integrations, having successfully led over 40 business transactions.About Pacific Green Technologies, Inc.Pacific Green Technologies, Inc. is focused on addressing the world's need for cleaner and more sustainable energy. The Company offers BESS, Concentrated Solar Power (CSP) and Photovoltaic (PV) energy solutions to complement its marine environmental technologies and emissions control divisions. For more information, visit Pacific Green's website: www.pacificgreentechnologies.comNotice Regarding Forward-Looking Statements:This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, any potential business developments and future interest in the Company's battery, solar and emissions control technologies.Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, general economic and political conditions, and the ongoing impact of the COVID-19 pandemic. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in the Company's annual report on Form 10-K for the most recent fiscal year, the Company's quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.Contact:Scott Poulter, Chairman & CEOPacific Green TechnologiesT: +1 (302) 601-4659SOURCE: Pacific Green Technologies, Inc. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
SYDNEY, AU, Oct 17, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, and Endpoints News present a webinar for biotechs considering the clinical research opportunities in Asia Pacific and the regulatory pathways to achieving FDA approval.Novotech has operations across Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late phase biotech clinical research.The webinar features regulatory affairs and investment leaders from North America and Asia Pacific who will discuss:- why biotech companies are increasingly exploring clinical opportunities in Asia Pacific to generate diverse, globally accepted clinical trial data- what actionable strategies can be implemented to leverage Asia Pacific's recruitment potential to accelerate your clinical development- how Phase 1 data from Australia is acceptable to the FDA and can be used to launch global drug development programs- deep insight into processes for designing and delivering a robust clinical program- biotech challenges and opportunities in the post-COVID environment with a focus on global investments and drug pipelinesRegister for the webinar here https://webinars.endpts.com/the-biotech-landscape-market-trends-priorities-predictions-and-pathways-to-fda-approval/October 18, 20221:00 pm - 2:00 pm EDTThe industry leaders presenting include:- Yi Larson, Chief Financial Officer of LianBio. Formerly Executive Vice President and Chief Financial Officer at Turning Point Therapeutics, Inc., and Goldman Sachs & Co. LLC, Managing Director of Healthcare Investment Banking- Kasey Kime, Director of Regulatory Affairs for Novotech's in-house consulting group, BioDesk- Dr. Jeanne M. Novak, President and CEO of CBR International Corp., a full-service product, clinical, and regulatory strategy group- Dr. Fred Cohen, a Co-Founder and Chairman of Monograph Capital Partners. He is also a Co-Founder and Senior Managing Director at Vida Ventures.Novotech has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
SYDNEY, Sep 5, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology drugs.Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.The clinical data compiled by GlobalData for Novoteoch also found that: "By the end of 2021 40% of active immuno-oncology clinical trials involved at least one location in the Asia-Pacific region, with majority of trials conducted in China, followed by Australia, South Korea, Japan and Taiwan. In the APAC region, the proportion of oncology trials doubled during 2017-2021. In China, the growth in oncology trials was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immune-oncology, and leadership in cell therapy."Download the Reports Here:IMMUNO-ONCOLOGY - ASIA PACIFIC - CLINICAL TRIAL LANDSCAPE https://novotech-cro.com/whitepapers/immuno-oncology-asia-pacific-clinical-trial-landscapeEVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5 https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes. Novotech's service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasizes problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
SINGAPORE, Sep 3, 2022 - (ACN Newswire via SEAPRWire.com) - Pertamina International Shipping (PIS) is increasingly targeting consumers in the international market. In addition to this expansion, PIS strives to continuously improve the quality and standard of service by exchanging knowledge and experiences with world energy companies.PT Pertamina International Shipping (PIS), in cooperation with PIS Pte Ltd (PIS PL), hosted a sharing session with BP Singapore Pte. Limited, Shell International Eastern Trading Co (SIETCO), and ExxonMobil Asia Pacific Pte Ltd. The meeting was held at the offices of each energy company on August 24-25, 2022, in Singapore.PIS, in cooperation with PIS Pte Ltd (PIS PL), hosted a sharing session with BP Singapore Pte. Limited, Shell International Eastern Trading Co (SIETCO), and ExxonMobil Asia Pacific Pte Ltd. The meeting was held at the offices of each energy company on August 24-25, 2022, in Singapore.During the sharing session, PIS discussed vetting, inspection, and vessel acceptance or vessel examination and inspection. The event was attended by PIS Director of Operations Arief Kurnia Risdianto, PIS PL Managing Director Brilian Perdana, Crude and Gas Operation (CGO) Vice President Harris Abdi Sembiring, and PIS Loss Prevention Safety Quality (LPSQ) Manager Soleh Komaruddin.BP Singapore Pte Ltd Vetting and Clearance Senior Manager, ExxonMobil Asia Pacific Pte Ltd Asia Pacific Supply Coordinator, ExxonMobil Asia Pacific Pte Ltd Mogas Lead, ExxonMobil Asia Pacific Pte Ltd Global Senior Marine Operations, SIETCO Mogas Operation Team Lead, SIETCO Head of Marine, SIETCO Senior Originator, and more were also in attendance at this meeting.The meeting was also a PIS endeavor to escalate acceptance of its ships at the terminals of world energy participants such as BP, Shell, and Exxon to showcase the existence and quality of PIS in international settings. In the maritime and energy sectors, these companies are significant participants that dominate the tanker chartering market called the Seven Sisters.PIS Director of Operations, Arief Kurnia Risdianto, explained PIS performance which has now explored 12 international routes. PIS ships have met international shipping standards, including the Paris MOU for sailing requirements on the European continent and a Certificate of Compliance from the United States Coast Guard (USCG)."PIS is the largest tanker operator in Southeast Asia, currently operating around 439 vessels with extensive experience serving the domestic and regional market," he said.Experience of PIS in serving the regional market is recorded by many international customers, including Vitol, Petronas, Trafigura, BP, Badak LNG, ExxonMobil, Petrobras, Chevron, Saudi Aramco, Shell, and many more.As the Integrated Marine Logistics Sub Holding of PT Pertamina (Persero), PIS business includes shipping, marine services, port services, port and jetty management (port ownership), storage tanks, and other related services.PIS owns two VLCCs, namely, Pertamina Pride and Pertamina Prime, with a capacity of 2 million barrels and incurs the Eco-Green Vessel concept. The two VLCCs are tangible manifestations of PIS endeavor to lead the marine and logistics business in both domestic and international markets.Besides oil and gas, PIS expands its business potential to various segments and cargo types, including petrochemicals with medium-range chemical-specific vessel assets called PIS Precious.In the meantime, to comply with regional trading and improve its role in the global market, Tanjung Uban offers an integrated terminal managed by the PIS subsidiary.PIS CEO Erry Widiastono said that the company has prepared a roadmap to support energy transition programs. "PIS will anticipate the future of vessels business, specifically the greener vessels. For example, vessels responsible for gas shipping such as LPG, LNG, and many others. In the future, we will anticipate the progress of the renewable energy sector," said Erry.About Pertamina International Shipping (PIS)As the Integrated Marine Logistics Sub Holding, PT Pertamina International Shipping (PIS) consistently stimulates Indonesia's economic growth through safe and sustainable operation, becomes a trusted and reliable maritime partner, and promotes value for the stakeholders in running their business. See https://pertamina-pis.com/. Media Contact:M Aryomekka FirdausCorporate SecretaryM: +62-811-872-272E: aryomekka@pertamina.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
Singapore, Aug 22, 2022 - (JCN Newswire via SEAPRWire.com) - Jurong Port, Mitsubishi Heavy Industries Asia Pacific (MHI-AP), a subsidiary of Mitsubishi Heavy Industries, and JERA Asia, a subsidiary of JERA, today concluded a Memorandum of Understanding (MoU) to jointly explore establishing a 100% ammonia direct combustion power plant on Jurong Island, Singapore, which houses the country's chemical and energy industries.Under the MoU, a joint study will be conducted, where a 60MW class gas turbine combined cycle plant fueled by 100% ammonia is planned to be set up to produce carbon-neutral electricity, as well as stimulate ammonia demand to be ready for ammonia bunkering in future.This MoU builds upon an initial agreement between Jurong Port and MHI-AP signed in August 2021 for a pre-feasibility study on ammonia direct combustion technology for green power generation, which was concluded successfully in March 2022.In February this year, the Singapore government raised its climate ambition to achieve net-zero CO2 emissions by or around 2050. This project is in alignment with the overall national decarbonization goals, as it aims to utilize ammonia - which can efficiently transport and store hydrogen in a liquid state at low cost - as a fuel to generate carbon-free electricity, and as the main bunkering fuel in future to decarbonize the maritime sector. The MoU will hence explore the viability and commercialization of ammonia for these purposes."We feel this MoU could help pave the way for encouraging the adoption of hydrogen in Singapore through aggregation of demand across multiple sectors, mainly the power sector and the maritime sector, thereby addressing the chicken-and-egg conundrum of infrastructure versus demand needs for maritime and domestic power generation. This collaboration is certainly consistent with the spirit of reinforcing Singapore's premier bunkering hub status - for current, transition and future fuels," said Ooi Boon Hoe, Chief Executive Officer, Jurong Port.Osamu Ono, Managing Director, MHI-AP, said: "Ammonia, which consists of hydrogen and nitrogen, is a highly efficient hydrogen carrier and can be directly combusted as a carbon neutral fuel, thereby contributing to the establishment of a robust hydrogen value chain. At MHI, we believe that ammonia and hydrogen are key fuels that can help countries meet their net zero goals, and this MoU is an exciting opportunity for us to contribute our technology and expertise to achieve sustainable development in Singapore and subsequently realize the global sustainability agenda.""JERA is committed to providing cutting edge solutions to the world's energy issues and is actively working to strengthen both the ammonia and hydrogen value chains. We believe this MoU offers a unique opportunity to support Singapore's decarbonization efforts while advancing the ammonia technology development for carbon neutral power generation. Through initiatives like this, JERA will leverage its experience and capabilities to help countries to reach their net-zero CO2 emissions targets and to build a clean energy supply chain in the region," said Toshiro Kudama, Chief Executive Officer, JERA Asia.Together, the three companies will contribute to achieving net-zero CO2 emissions in Singapore by leveraging their technology, resources and expertise.About Jurong PortJurong Port (JP) is a world-class multipurpose port operator serving as Singapore's premier gateway for general and bulk cargo. Its port operating expertise includes efficient handling of general, bulk, and containerised cargo at JP Homeport, management and operations of the Tuas Offshore Marine Centre, Lighter Terminals in Penjuru and Marina South as well as overseas ports in China and Indonesia. JP also owns and operates two of the most modern tank storage terminals in Singapore - Jurong Port Tank Terminals (JPTT) and Jurong Port Universal Terminal (JPUT). With a combined storage capacity of almost 3 million m3, JP is the largest independent storage terminal operator in Singapore. JPUT, in particular, supports approximately 30% of Singapore's annual bunkering volume, reinforcing the nation's position as the top bunkering hub in the world. JP caters to regional and domestic markets across diverse industry supply chains which include construction, shipbuilding, offshore, transport, logistics, energy, and manufacturing industries. JP's local and overseas terminals handled a total of 70 million tons of general and bulk cargo and more than half a million TEUs in 2021. Amongst others, JP won the Lloyd's List Asia Pacific Port/ Terminal Operator of the Year Award in 2018 and the National Infocomm Award for Most Innovative Use of Infocomm Technology (Private Sector) in 2016.For more information, please visit www.jp.com.sg or follow us on Facebook and Linkedin.About Mitsubishi Heavy Industries Asia Pacific (MHI-AP)Mitsubishi Heavy Industries Asia Pacific Pte. Ltd. (MHI-AP) is a subsidiary of Mitsubishi Heavy Industries, Ltd. (MHI), one of the world's leading industrial firms. Located in Singapore, the Asia Pacific headquarters supports the growth of markets in Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Myanmar, India, Australia and other parts of the region. MHI-AP builds on its global outlook and deep local insights to deliver integrated solutions to the region in urban development and infrastructure, energy and utilities, as well as logistics and transportation. As a market leader in Asia Pacific, MHI-AP provides reliable and innovative solutions that move the world forward.For more information, visit www.mhi.com/.About JERAEstablished in 2015, JERA is an equal joint venture of two major Japanese electric companies, TEPCO Fuel & Power Incorporated and Chubu Electric Power Company. JERA is an energy company with global reach that has strength in the entire energy supply chain, from participation in LNG upstream projects and fuel procurement, through fuel transportation to power generation. JERA's mission is to provide cutting edge solutions to the world's energy issues, by offering energy supply models established in Japan through JERA's global operations to other countries. JERA has recently established its New Corporate Vision for 2035, indicating its goal "To scale up its clean energy platform of renewables and low greenhouse gas thermal power, sparking sustainable development in Asia and around the world". With this context, JERA is interested in the development of the ammonia value chain in Singapore and the overall strategic vision towards sustainable development in Asia and around the world.For more details: https://www.jera.co.jp/english/About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
SINGAPORE, Jun 1, 2022 - (ACN Newswire via SEAPRWire.com) - Azelis, a leading innovation service provider in the specialty chemicals and food ingredients industry, announces the opening of its Regional Innovation Center (RIC) for Food & Nutrition (F&N) in Singapore, further demonstrating the Group's commitment to continuously invest in its innovation capabilities.The RIC will generate a wealth of possibilities for food innovation towards healthier and tastier solutions through pioneering, ready-to-use formulations with advanced, sustainable ingredients. Functioning as an innovation catalyst for the F&N ecosystem in Asia Pacific, the RIC is an essential milestone in Azelis' growth strategy, strengthening the Group's position as a leading provider of innovative solutions.In addition to the RIC, Azelis' five F&N application laboratories across Asia Pacific form a regional innovation network that brings together the technical expertise and formulation capabilities of the local and regional teams for greater synergy. This setup allows Azelis to serve the F&N market more efficiently, realize advanced ingredient synergies and develop ground-breaking formulations and sustainable solutions that will be cascaded across the region.Vikash Raj, Asia Pacific Innovation Director, remarks: "The RIC allows us to support our customers in their projects by developing innovative solutions for all stages of the formulation process from concept to final product, across industry applications in Bakery, Beverage, Confectionery, Dairy and Savory. Focusing on innovation in new products and applications is our objective, and thanks to our comprehensive lateral value chain, we have access to sustainable building blocks for food and beverage formulations. Our vision for the RIC is to positively impact our sustainability, health, and wellness ambitions by creating pioneering formulations that address nutrition and health challenges and bring healthy solutions to the mainstream market."Laurent Nataf, CEO & President Asia Pacific, comments: "With more than 20 laboratories in the region covering our key market segments, we have significantly invested in our innovation capabilities across Asia Pacific to ensure we deliver on our brand promise, 'Innovation through formulation'. Our regional innovation network builds on our formulation expertise and technical capabilities by encouraging greater collaboration across our teams to strengthen cross-country synergies, increase efficiency, and ensure consistent formulation success for our customers. We look forward to further strengthening our partnerships with our customers and principals by allowing them to leverage the strength of our ever-growing innovation network capabilities, remaining their innovation partner of choice."To find out more, watch a video introducing the Regional Innovation Center in Singapore. https://youtu.be/RDJ4OhQcDh8Contact informationAzelisLillian Ying Asia Pacific Corporate Communications ManagerT: +65 9855 8818E: lillian.ying@azelis.comAbout AzelisAzelis is a leading global innovation service provider in the specialty chemical and food ingredients industry present in over 50 countries across the globe with over 3,000 employees. Our knowledgeable teams of industry, market and technical experts are each dedicated to a specific market within Life Sciences and Industrial Chemicals. We offer a lateral value chain of complementary products to more than 51,000 customers, supported by ~2,300 principal relationships, creating a turnover of EUR2.8 billion (2021). Azelis Group NV is listed on Euronext Brussels under ticker AZE.Across our extensive network of more than 60 application laboratories, our award-winning staff help develop formulations and provide technical guidance throughout the customers' product development process. We combine a global market reach with a local footprint to offer a reliable, integrated and unique digital service to local customers and attractive business opportunities to principals. EcoVadis Platinum rated, Azelis is a leader in sustainability. We believe in building and nurturing solid, honest and transparent relationships with our people and partners.Impact through ideas. Innovation through formulation.http://www.azelis.com/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
MELBOURNE, May 23, 2022 - (ACN Newswire via SEAPRWire.com) - An osteoporotic fracture occurs every three seconds worldwide.(1) More than 50 per cent of the world's hip fractures are expected to occur in the Asia Pacific over the next two decades.(2) This is due to the region's rapidly aging population, mounting urbanisation, and subsequent increase in sedentary lifestyles.(2)A digital media kit is available at www.apcotoolkit.org.In an effort to stem this health crisis, the Asia Pacific Consortium on Osteoporosis (APCO) will launch a Bone Health QI Tool Kit for healthcare professionals on Tuesday, May 24, 2022, to promote quality improvement of osteoporosis care.This world-first tool kit, encompassing multiple components in the screening, diagnosis, and management of osteoporosis, will help to promote multi-sector healthcare professional engagement and cooperation, to address this looming healthcare catastrophe.- Osteoporosis - the most common disease - is characterised by porous and brittle bones, whose density and quality are poor, resulting in structural skeletal deterioration.(1)- The disease is greatly under-diagnosed, and under-treated in Asia, even among those at highest risk who have already fractured.(3)- The Asia Pacific is home to 4.5 billion people and vastly different healthcare systems.(4)- Over the next two decades, a staggering 319 million people aged 50+ from the Asia Pacific are projected to be at high risk of osteoporotic fracture.(5)- Moreover, the number of hip fractures are projected to more than double in Asia, from 1.13 million in 2018, to 2.54 million in 2050.(5)References:(1) International Osteoporosis Foundation (IOF). Capture the fracture. [Oct, 2021]; Available from: https://www.capturethefracture.org/about.(2) Chandran M, et al., Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region. Osteoporos Int., 2021. 32(7): p. 1249-1275.(3) International Osteoporosis Foundation. Key statistics for Asia. [cited October 2022]; Available from: https://www.osteoporosis.foundation/facts-statistics/key-statistic-for-asia.(4) Oden, A., et al., Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int, 2015.26(9): p. 2243-8.(5) Cheung, C.-L., et al., An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. Osteoporosis and sarcopenia, 2018. 4(1): p. 16-21.For more information contact: Kirsten Brucekirstenbruce@vivacommunications.com.au Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
BANGKOK, May 4, 2022 - (ACN Newswire via SEAPRWire.com) - Asia Pacific Rail 2022, the leading annual gathering of Asia Pacific's rail leaders, will take place in Bangkok on 11-12 May 2022. After an absence of more than three years, owing to the COVID-19 pandemic, the event marks the first time that the region's rail leaders have been able to gather together since 2019. The 2022 edition will gather over 1,000 of the region's leading rail professionals and is endorsed by the Thailand Convention & Exhibition Bureau.All of Thailand's major rail operators and authorities will be represented at the event: Asia Era One Co. Ltd, Bangkok Expressway & Metro Public Company Limited, Bangkok Mass Transit System Public Company, Department of Rail Transport, Mass Rapid Transit Authority of Thailand, Office of Transport Policy & Planning, State Railway of Thailand and Thailand's Ministry of Transport will all be sharing updates on the latest plans and opportunities for Thailand's rail industry.International rail operators from Singapore, Australia, Malaysia, Indonesia, Cambodia, Philippines and India will also be onsite at the event, including Land Transport Authority Singapore, Metro Trains Melbourne, Prasarana Malaysia Berhad and PT MRT Jakarta. Hong Kong's MRT Corporation will be joining the event virtually owing to the continued travel restrictions."With borders across the region opening up, the Asia Pacific Rail team have been working tirelessly to bring this outstanding group or rail operators and technology partners together under one roof for the first time in years," says Paul Clark, Managing Director - Asia forTerrapinn. "We're delighted to be bringing the event to Thailand for the first time and for our attendees to hear about the fantastic opportunities available in its rail sector. This is the event where the region's rail leaders chart the future of rail and we can't wait to get started."Asia Pacific Rail will offer five tracks of content across the two days - Digital Rail; Signalling & Communications; Operations, Maintenance & Asset Management; Mainline and Project Updates and attendees will be free to move between the content tracks as they wish.Keynote speakers at the event include:- Pichet Kunadhamraks, Deputy Director-General, Department of Rail Transport, Ministry of Transport, Thailand- Punya Chupanit, Director General, Office of Transport and Traffic Policy and Planning- Vithaya Punmongkol, Deputy Governor, Mass Rapid Transit Authority of Thailand- Ling Fang, President Asia Pacific, Alstom- Jacob Kam, Chief Executive Officer, MTR Corporation*- Chua Chong Kheng, Deputy Chief Executive - Infrastructure and Development, Land Transport Authority- Catherine Baxter, Chief Operating Officer, Metro Trains Melbourne- TC Chew, Director, Global Rail Business Leader, Arup- Steven Xiong, CTO in Rail Industry, Huawei EBG- Arezki Touat, Senior Vice President, Systra Asia- Sumit Srisantithum, Chief Operating Officer, Bangkok Mass Transit System Public Company- Tony Lee, Operations Director, MTR Hong Kong*- Toby Tiberghien, Turnkey & Rolling Stock Director, East Asia, Alstom- Narelle Rogers, ANZ Rail Systems Lead, Jacobs- Adi Lau, Managing Director - Mainland China Business & Global Operations Standards, MTR Corporation*- Alvin Gee, Deputy Managing Director - Administration, Bangkok Expressway and Metro Public Company Limited*Joining virtuallyMore than 50 sponsors and exhibitors will be onsite demonstrating the latest technologies and innovations to help the region's rail operators, including Diamond Sponsors Alstom, Huawei, Platinum Sponsors, Siemens & Thales, and Gold Sponsors Arup, Jacobs and KONE. There will also be a technology showcase theatre running on the exhibition floor where attendees can enjoy practical insights into deploying the latest technologies in their rail operations.Press attendance is complimentary. Enquiries should be directed to: Christine LeeMarketing Director Terrapinn Asia christine.lee@terrapinn.comAbout Asia Pacific Rail 2022Asia Pacific Rail 2022 will take place at BITEC in Bangkok on 11-12 May 2022 in Halls EH 103 and 104. All attendees will be required to show proof of vaccination for entry and masks will be worn onsite.About TerrapinnTerrapinn has been sparking ideas, innovations and relationships that transform business for over 30 years. Using our global footprint, we bring innovators, disrupters and change agents together, discussing and demonstrating the technology, strategies and personalities that are changing the way the world does business. Whether you're looking to make new connections, introduce product or inspire change in your industry, we invite you to join us as agitators of change. Terrapinn - spark something. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
- 摩特在新加坡大士超级港附近开设 700,000 平方英尺的全新区域仓库- 摩特亚洲集散中心将强化公司在亚太地区的供应链和物流能力- 亚太地区将是 摩特未来几年中最大的市场之一中国北京, 2022年3月2日 - (亚太商讯 via SEAPRWire.com) - 摩特全新最先进区域性仓库 摩特亚洲集散中心 (Motul Asia Hub) 正式投入运营,摩特亚太区首席执行官 Lionel Dantiacq 亲临剪彩仪式。摩特亚洲集散中心位于新加坡全新大士超级港的太平洋物流中心 (PLG)。这个 700,000 平方英尺的中心将整合仓储和库存环节,进一步支持和强化 摩特在整个亚太地区的供应链运营。摩特生产的高性能润滑油和机油应用范围广泛,是行业中的领先品牌,在亚太地区的影响力与日俱增,该集散中心将进一步夯实公司的卓越能力。这个亚洲集散中心的推出对 摩特而言是一件极为重要的举措,将助力公司实现其加快增长的雄心目标。以现代供应链解决方案应对复杂市场,简化业务运营。仓库所在的地理位置具有独特优势,可以更快、更便捷的空运和海运方式,将产品运送到区域内的各个市场,加快产品周转时间。集散中心靠近大士超级港和新加坡樟宜机场,这也是提高供应链效率的最佳选择。中心配备了最新技术,包括一个联网安全库存管理系统,可随时访问最新信息。摩特通过与 PLG 和保税区合作,在该地区建立了一个高效分销网络,为经销商提供最佳支持。保税区最大的优势之一是:对进口再出口的货物免征商品及服务税,通过这种方式减少商品处理时间和间接成本,提高效率。摩特继续拓展亚太市场,超越客户期望。对于 摩特而言,为客户提供最高水平的服务始终是公司的核心价值观之一。这个集散中心的推出,将帮助公司更好地满足消费者不断增长的需求。汽车行业发展日新月异,大量的新技术每天都在带来新突破。在这个集散中心的帮助下,摩特将可以赶在该地区竞争对手之前,将新开发的产品系列推向市场。为应对出行领域日新月异的需求,摩特全力拓展品类范围,强化产品创新。多年来,亚洲一直是 摩特全球业务的重要市场,随着该地区对润滑油的需求不断增加,这个市场对公司的重要性也与日俱增。摩特亚太区制定了一个明确的目标,确保可以满足客户最严格的要求。随着亚洲集散中心的启动,摩特将以快速可靠的方式向该地区的客户提供高质量的系列产品。对于 摩特而言,这是实现该目标的唯一方式。这个集散中心将成为 摩特的里程碑成就,帮助公司在未来始终成为客户首选品牌。Lionel Dantiacq | 摩特亚太区首席执行官"今天我们的 摩特亚洲集散中心正式启动,这是我们在亚洲工作的延续,在亚洲快速增长和转型的过程中实现发展目标。通过这个集散中心,我们将简化公司在该地区的供应链,以更高的效率将产品送到客户手中。满足客户的需求是我们的核心宗旨。这个集散中心也印证了我们向成千上万选择 摩特客户的承诺。该中心将帮助我们拓展业务范围,开拓新市场,将最优质的 摩特产品带给新老客户,满足他们在润滑方面的所有需求。"关於 摩特摩特是源自法国的世界顶尖品牌,专注透过技术研发、制造及销售高科技机油 (汽车、摩托车和其他车辆) 及润滑油。品牌提供一系列日常汽车产品,包括 8100、7100、H-tech、RBF 系列、ATF、CVTF 及 DCTF 等,致力保持机器的原始状态,以发挥最佳表现和稳定性。150 多年来,摩特因其产品质量、创新能力和所参与的竞争领域而获得一致认可,同时也是公认的合成机油专家。 早在 1971 年,摩特就采用当时只应用在航天科技的酯类技术,推出300V 润滑油,成为开创 100% 合成机油配方的首家润滑油制造商。2021 年标志着 Motul 300V 的 50 周年诞辰。摩特一直都与不同的汽车制造商及赛车队伍合作,协助他们在赛车研发上更进一步。为此,摩特积极参加世界各地不同的比赛,并成为多支冠军车队的官方供应商。摩特非常着重亚太地区的市场发展。多年来,公司已在区内成功立足,并积极扩展业务。现时摩特在亚太区内已经拥有三座大型的生产设施,以及两所研发中心,专注於调较适用於亚洲地区气候的配方,应对区内不断增长的业务和需求。MOTUL Asia Pacific Pte. Ltd1A International Business Park, #06-03Singapore 609933www.motul.com如欲了解更多,請透過電郵 (pr@motul.com.sg) 與 摩特聯絡。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
- New 700,000 sq ft Motul regional warehouse opened near Singapore's Tuas Mega Port- Motul Asia Hub to enhance supply chain and logistics across Asia Pacific region- Asia Pacific set to become one of the biggest markets for Motul in coming yearsSingapore, Mar 2, 2022 - (ACN Newswire via SEAPRWire.com) - Lionel Dantiacq, CEO of Motul Asia Pacific, cut the ribbon to launch a new, state-of-the-art Motul regional warehouse, the Motul Asia Hub, on 1st March 2022. The Motul Asia Hub is located at the Pacific Logistics Group (PLG), Tuas Headquarters at Singapore's brand new Tuas Mega Port. The 700,000 sq ft facility will support and enhance Motul's supply chain across the Asia Pacific region by consolidating warehousing and inventory operations. The Hub will play a monumental role as Motul continues to build a greater presence across the APAC region and further strengthens its leadership in high performance lubricants and fluids for all uses.Motul is excited about the launch of the Asia Hub, which will be essential to support its ambitions of accelerated growth. A modern supply chain solution will tackle the complexities of the market and streamline business operations.The unique location of the warehouse will provide a geographical advantage for faster and easier transit with quick turnaround times for both air and sea shipments to all regional markets. The close proximity to the Tuas Mega Port makes the location of the warehouse optimal for improved supply chain efficiency. The facility will also house the latest technology, including a secure web-based inventory management system for instant access to up to date information.Through the partnership with PLG and their bonded facilities, Motul will ensure a streamlined distribution network across the region to support its dealers. A unique aspect of the bonded facilities is the exemption of GST imposed on goods imported to be re-exported, reducing processing time and overhead costs leading to ultimate efficiency.Motul continues to expand its market reach across APAC and exceed customer expectations. Providing the highest level of service to its customers is a core value at Motul and the Hub will enable it to meet the growing demands of the consumers. With an ever-changing automotive industry and new technologies pushing boundaries every day, the Hub will allow Motul to bring newly developed product lines to market faster than their competitors across the region. Motul aims to broaden its category reach and embrace product innovations for changing mobility requirements.Asia has been a key market to Motul's global business for many years, and the region continues to grow as the demand for lubricants ramps up. Motul Asia Pacific has set a clear target to focus on the needs of its discerning customers. With the launch of the Asia Hub, Motul will deliver its high-quality range of products to customers across the region in the only way they know how, fast and reliable. The Hub will also serve as a landmark for Motul to remain a preferred choice for customers for years to come.LIONEL DANTIACQ | CEO Motul Asia Pacific"The launch of our new Motul Asia Hub today represents an exciting continuation of our efforts to capitalize on Asia's dynamic growth and transformation. With this Hub, we aim to streamline our supply chain in the region and bring our products to customers with greater efficiency. Catering to the customer's need is at the core of who we are, and this Hub serves as a symbol of our dedication to hundreds of thousands of customers who choose Motul. The Hub will play a monumental role in expanding our reach, tapping new markets and bringing these amazing Motul products to existing and new customers for all their lubrication needs."ABOUT MOTULMotul is a world-class French company specialised in the formulation, production and distribution of high-tech engine lubricants (two-wheelers, cars and other vehicles) as well as lubricants for industry via its Motul Tech activity. Motul offers a whole range of products for everyday car use, including the 8100, H-tech, RBF series, ATF, CVTF and DCTF among others. Motul products ensure all parts of the car are kept in pristine condition to extract maximum performance and reliability.Unanimously recognised for more than 150 years for the quality of its products, innovation capacity and involvement in the field of competition, Motul is also recognised as a specialist in synthetic lubricants. As early as 1971, Motul was the first lubricant manufacturer to pioneer the formulation of a 100% synthetic lubricant, issued from the aeronautical industry, making use of esters technology: 300V lubricant. In 2021, Motul launched the newest iteration of the 300V with revolutionary technology, setting a new benchmark for high-performance lubricants.Motul is a partner to many manufacturers and racing teams in order to further their technological development in motorsports. It has invested in many international competitions as an official supplier for several championship winning racing teams.Motul is committed to its growing business presence in Asia Pacific. Over the years, the company has expanded operations significantly. Currently it has 3 major manufacturing facilities and 2 R&D centres across the region to cater to the ever-growing demand. These centres focus on refining the lubricant technology for Asian climate and driving conditions, which are vastly different from Europe.MOTUL Asia Pacific Pte. Ltd1A International Business Park, #06-03Singapore 609933www.motul.comFor more information, please contact Motul at pr@motul.com.sg Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
HIROSHIMA, Japan, Nov 29, 2021 - (JCN Newswire via SEAPRWire.com) - Mazda Motor Corporation has been included in the Dow Jones Sustainability Indices' Asia Pacific Index for the fifth year running.The Dow Jones Sustainability Indices are among the longest-running(1) ESG investment indices(2) in the world. Corporations are assessed annually in the areas of environmental initiatives, social contribution, human resource development, corporate governance and compliance, and only those with outstanding sustainability performance in their industry are included.Mazda was selected on the basis of a survey questionnaire and a comprehensive review of the company's Sustainability Report, Annual Report and official website that highly evaluated Mazda's CSR initiatives and information disclosure practices. Mazda was one of 77 Japanese companies and three automotive companies chosen from among approximately 600 major corporations assessed for inclusion in the DJSI Asia Pacific Index this year.Mazda will continue to prioritize CSR in all initiatives and contribute to the development of a sustainable society. The company aims to build a special bond with customers and envisions a world in which cars exist in harmony with the earth, people and society.For more information:Mazda Sustainability Report(3)https://www.mazda.com/en/csr/report/download/Annual Reporthttps://www.mazda.com/en/investors/library/annual/(1) Dow Jones Sustainability Indices were established in 1999 by S&P Dow Jones Indices and RobecoSAM.(2) Investment indices based on performance in the areas of environment, social contribution and governance (ESG).(3) The 2021 edition will be published within Fiscal year ending March 2022. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)
Singapore, Oct 20, 2021 - (ACN Newswire via SEAPRWire.com) - More than 50 per cent of the world's hip fractures are expected to occur in the Asia Pacific by the year 2050.In a strong effort to stem the tide, and to promote quality care in osteoporosis, the Asia Pacific Consortium on Osteoporosis (APCO) has launched a world-first, interactive, educational osteoporosis resource – the APCO Health Care Professional (HCP) Peer to Peer Educational Modules – today, to mark World Osteoporosis Day (Wednesday, October 20).The survival of those who sustain an osteoporotic fragility fracture is significantly compromised for up to six years, with patients facing twice the risk of death within the first year. Furthermore, a prior fracture at any site doubles a person's risk of refracture. Yet despite these alarming statistics, more than 80 per cent of fragility fracture patients are neither assessed, nor treated, placing a substantial, but importantly, preventable burden on already strained healthcare systems. This is despite the extensive availability of safe and effective osteoporosis management strategies.Minimum clinical standards for the assessment and management of osteoporosis are therefore urgently required in the Asia Pacific, to inform clinical practice guidelines, and improve osteoporosis care. It was with this aim in mind that APCO launched ‘The APCO Framework' in January, 2021. ‘The Framework' comprises 16 minimum clinical standards that serve as a benchmark for the provision of best practice osteoporosis care in the Asia Pacific.The APCO HCP Peer to Peer Education Modules will offer physicians a comprehensive, evidence-based resource encouraging widescale implementation of the minimum clinical standards of care for osteoporosis advocated in The APCO Framework. This will enable the delivery of best practice osteoporosis care throughout the Asia Pacific – the world's fastest ageing region.According to APCO Chairperson, and Director of the Osteoporosis and Bone Metabolism Unit, Singapore General Hospital, Dr Manju Chandran, Singapore, there are significant inconsistencies in clinical practice guidelines in the Asia Pacific for the management and prevention of osteoporosis and fragility fractures. These guidelines vary extensively in scope and recommendations. There is also a lack of information available on adherence to national guidelines in daily clinical practice."It is to address this care gap, that APCO has developed an interactive, 17-module educational series today, to arm osteoporosis champions in the Asia Pacific, with information, supporting data, topical literature summaries, and best practice examples that support and emphasise each of The APCO Framework's 16 minimum clinical standards and emerging themes in osteoporosis care."Increasing awareness and education among healthcare professionals in the Asia Pacific is imperative to bringing change to the real-world clinical practice of osteoporosis care and fracture prevention," said Dr Chandran."The Asia Pacific is home to 4.5 billion people, rapidly ageing populations, and vastly different healthcare systems. "An overwhelming 319 million people aged 50 years and over from the Asia Pacific are projected to be at high risk of osteoporotic fracture over the next two decades, while more than half of the world's hip fractures are expected to occur in the region by 2050," Dr Chandran said."Singapore, where I live, for instance, has one of the highest hip fracture rates in the world, with a four-to-five-fold increase in incidence noted over a recent 30-year period."The incidence of osteoporotic fractures in Singapore is projected to rise from more than 15,000 in 2017, to 24,100 by 2035, an increase of 57.9 per cent. The total economic burden (including both direct and indirect costs) associated with these fractures is projected to grow from SGD 183.5 million (USD 214 million) in 2017, to SGD 289.6 million (USD 136 million) by 2035."After one year, two in five people who sustain a hip fracture will be unable to walk independently, while two-thirds will encounter difficulty performing at least one essential daily task."Economically, the burden of current treatment of a single hip fracture in the Asia Pacific is extremely high, equating to approximately 19 per cent of our region's per-head gross domestic product (GDP)," said APCO Committee member, Consultant in Endocrinology and Diabetes at Tun Wah Hospital, and Chairperson of the Guideline for the Management of Postmenopausal Osteoporosis in Hong Kong, Dr Ip Tai-Pang,Hong Kong SAR.In Hong Kong SAR alone, the direct medical costs of hip fractures was an estimated USD 85 million in 2018, the costs for which are projected to increase to USD 243 million by 2050."Given the anticipated exponential growth in fragility fractures due to the region's rapidly ageing population, mass urbanisation and our increasingly sedentary lifestyles, we must act now," Dr Ip said."Osteoporosis experts can use the new APCO HCP Education Modules either in full, or in part, to inspire and further inform their peers and professional communities on those at high-risk for fracture who require identification and assessment, based on their medical and fracture history, risk factors, co-occurring diseases, country-specific osteoporosis screening tool results, and falls risk."Supporting data on the administration, duration, monitoring of, and adherence to, various treatment interventions and their associated side-effects, as well as the critical need for long-term management plans, also feature in the APCO modules," said Dr Ip.Osteoporosis is vastly under-diagnosed and under-treated. Disturbingly, millions of people worldwide at high risk of fracture remain unaware of this underlying, silent disease. Championed by the International Osteoporosis Foundation (IOF), World Osteoporosis Day is dedicated to raising global awareness of the importance of prevention, diagnosis and treatment of osteoporosis and musculoskeletal diseases."This World Osteoporosis Day, we encourage healthcare providers, policy makers, patients, members of the public, and the media on a global, regional and national stage, to recognise the monumental human and socio-economic burden of osteoporosis, and the severe impact of fractures on a patient's independence and quality of life," IOF Chief Executive Officer, and APCO Executive Committee member, Dr Philippe Halbout, Switzerland said."One of the emerging osteoporosis themes outlined in the APCO HCP Education Modules, is the importance of Asia Pacific-wide systemic integration of case identification and management at all levels of health systems, including acute care services, when patients present with fractures through Post Fracture Care Coordination Programs, such as Fracture Liaison Services (FLS)."These coordinated systems of care aim to identify, treat and monitor patients presenting with a fragility fracture. Intervention can reduce fractures by up to 50 per cent, deliver substantial financial savings, and ultimately, save lives," said Dr Halbout."Today's launch of the APCO Education Modules demonstrates the organisation's ongoing commitment to achieving greater consistency in national and regional clinical practice guidelines for the screening, diagnosis, and management of osteoporosis in the Asia Pacific."To request access to The APCO Education Modules, head to: apcobonehealth.org/apco-education-modules. To learn more, visit www.apcobonehealth.org or follow APCO on LinkedIn: asia-pacific-consortium-on-osteoporosis. About APCOThe Asia Pacific Consortium on Osteoporosis (APCO) comprises osteoporosis experts from 19 countries in the Asia Pacific, charged with developing tangible solutions to the substantive challenges involving osteoporosis management and fracture prevention in this most populated and fastest growing part of the world. APCO's mission is to engage with relevant stakeholders, including healthcare providers, policy makers and the public, to help develop and implement country and region-specific programs for the prevention and treatment of osteoporosis, and its complication of fragility fractures, in the Asia Pacific.About osteoporosis in the Asia Pacific region- Osteoporosis is estimated to account for nearly nine million fractures each year, noting more than 200 million people worldwide live with osteoporosis.- Osteoporotic fractures among Asia-Pacific populations are expected to increase exponentially, due to the region's rapidly aging population, mounting urbanisation, and subsequent increase in sedentary lifestyles.- Osteoporosis is greatly under-diagnosed and under-treated in Asia, even among those at highest risk who have already fractured. In most developing countries of the Asia Pacific, especially in rural areas, DXA technology is not widely available.About World Osteoporosis DayFalling each year on October 20, World Osteoporosis Day raises awareness of bone health and osteoporosis prevention. This year's campaign, under the banner of ‘Take Action for Bone Health', calls for global action to fight osteoporosis and related fractures. See: www.worldosteoporosisday.org. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)
Singapore, Oct 20, 2021 - (ACN Newswire via SEAPRWire.com) - More than 50 per cent of the world's hip fractures are expected to occur in the Asia Pacific by the year 2050. In a strong effort to stem the tide, and to promote quality care in osteoporosis, the Asia Pacific Consortium on Osteoporosis (APCO) has launched a world-first, interactive, educational osteoporosis resource - the APCO Health Care Professional (HCP) Peer to Peer Educational Modules - today, to mark World Osteoporosis Day (Wednesday, October 20). The survival of those who sustain an osteoporotic fragility fracture is significantly compromised for up to six years, with patients facing twice the risk of death within the first year. Furthermore, a prior fracture at any site doubles a person's risk of refracture. Yet despite these alarming statistics, more than 80 per cent of fragility fracture patients are neither assessed, nor treated, placing a substantial, but importantly, preventable burden on already strained healthcare systems. This is despite the extensive availability of safe and effective osteoporosis management strategies. Minimum clinical standards for the assessment and management of osteoporosis are therefore urgently required in the Asia Pacific, to inform clinical practice guidelines, and improve osteoporosis care. It was with this aim in mind that APCO launched 'The APCO Framework' in January, 2021. 'The Framework' comprises 16 minimum clinical standards that serve as a benchmark for the provision of best practice osteoporosis care in the Asia Pacific. The APCO HCP Peer to Peer Education Modules will offer physicians a comprehensive, evidence-based resource encouraging widescale implementation of the minimum clinical standards of care for osteoporosis advocated in The APCO Framework. This will enable the delivery of best practice osteoporosis care throughout the Asia Pacific - the world's fastest ageing region. According to APCO Chairperson, and Director of the Osteoporosis and Bone Metabolism Unit, Singapore General Hospital, Dr Manju Chandran, Singapore, there are significant inconsistencies in clinical practice guidelines in the Asia Pacific for the management and prevention of osteoporosis and fragility fractures. These guidelines vary extensively in scope and recommendations. There is also a lack of information available on adherence to national guidelines in daily clinical practice. "It is to address this care gap, that APCO has developed an interactive, 17-module educational series today, to arm osteoporosis champions in the Asia Pacific, with information, supporting data, topical literature summaries, and best practice examples that support and emphasise each of The APCO Framework's 16 minimum clinical standards and emerging themes in osteoporosis care. "Increasing awareness and education among healthcare professionals in the Asia Pacific is imperative to bringing change to the real-world clinical practice of osteoporosis care and fracture prevention," said Dr Chandran. "The Asia Pacific is home to 4.5 billion people, rapidly ageing populations, and vastly different healthcare systems. "An overwhelming 319 million people aged 50 years and over from the Asia Pacific are projected to be at high risk of osteoporotic fracture over the next two decades, while more than half of the world's hip fractures are expected to occur in the region by 2050," Dr Chandran said. "Singapore, where I live, for instance, has one of the highest hip fracture rates in the world, with a four-to-five-fold increase in incidence noted over a recent 30-year period. "The incidence of osteoporotic fractures in Singapore is projected to rise from more than 15,000 in 2017, to 24,100 by 2035, an increase of 57.9 per cent. The total economic burden (including both direct and indirect costs) associated with these fractures is projected to grow from SGD 183.5 million (USD 214 million) in 2017, to SGD 289.6 million (USD 136 million) by 2035."After one year, two in five people who sustain a hip fracture will be unable to walk independently, while two-thirds will encounter difficulty performing at least one essential daily task. "Economically, the burden of current treatment of a single hip fracture in the Asia Pacific is extremely high, equating to approximately 19 per cent of our region's per-head gross domestic product (GDP)," said APCO Committee member, Consultant in Endocrinology and Diabetes at Tun Wah Hospital, and Chairperson of the Guideline for the Management of Postmenopausal Osteoporosis in Hong Kong, Dr Ip Tai-Pang, Hong Kong SAR. In Hong Kong SAR alone, the direct medical costs of hip fractures was an estimated USD 85 million in 2018, the costs for which are projected to increase to USD 243 million by 2050. "Given the anticipated exponential growth in fragility fractures due to the region's rapidly ageing population, mass urbanisation and our increasingly sedentary lifestyles, we must act now," Dr Ip said. "Osteoporosis experts can use the new APCO HCP Education Modules either in full, or in part, to inspire and further inform their peers and professional communities on those at high-risk for fracture who require identification and assessment, based on their medical and fracture history, risk factors, co-occurring diseases, country-specific osteoporosis screening tool results, and falls risk. "Supporting data on the administration, duration, monitoring of, and adherence to, various treatment interventions and their associated side-effects, as well as the critical need for long-term management plans, also feature in the APCO modules," said Dr Ip. Osteoporosis is vastly under-diagnosed and under-treated. Disturbingly, millions of people worldwide at high risk of fracture remain unaware of this underlying, silent disease. Championed by the International Osteoporosis Foundation (IOF), World Osteoporosis Day is dedicated to raising global awareness of the importance of prevention, diagnosis and treatment of osteoporosis and musculoskeletal diseases. "This World Osteoporosis Day, we encourage healthcare providers, policy makers, patients, members of the public, and the media on a global, regional and national stage, to recognise the monumental human and socio-economic burden of osteoporosis, and the severe impact of fractures on a patient's independence and quality of life," IOF Chief Executive Officer, and APCO Executive Committee member, Dr Philippe Halbout, Switzerland said. "One of the emerging osteoporosis themes outlined in the APCO HCP Education Modules, is the importance of Asia Pacific-wide systemic integration of case identification and management at all levels of health systems, including acute care services, when patients present with fractures through Post Fracture Care Coordination Programs, such as Fracture Liaison Services (FLS). "These coordinated systems of care aim to identify, treat and monitor patients presenting with a fragility fracture. Intervention can reduce fractures by up to 50 per cent, deliver substantial financial savings, and ultimately, save lives," said Dr Halbout. "Today's launch of the APCO Education Modules demonstrates the organisation's ongoing commitment to achieving greater consistency in national and regional clinical practice guidelines for the screening, diagnosis, and management of osteoporosis in the Asia Pacific."To request access to The APCO Education Modules, head to: apcobonehealth.org/apco-education-modules.To learn more, visit www.apcobonehealth.org or follow APCO on LinkedIn: asia-pacific-consortium-on-osteoporosis. About APCOThe Asia Pacific Consortium on Osteoporosis (APCO) comprises osteoporosis experts from 19 countries in the Asia Pacific, charged with developing tangible solutions to the substantive challenges involving osteoporosis management and fracture prevention in this most populated and fastest growing part of the world. APCO's mission is to engage with relevant stakeholders, including healthcare providers, policy makers and the public, to help develop and implement country and region-specific programs for the prevention and treatment of osteoporosis, and its complication of fragility fractures, in the Asia Pacific.About osteoporosis in the Asia Pacific region - Osteoporosis is estimated to account for nearly nine million fractures each year, noting more than 200 million people worldwide live with osteoporosis. - Osteoporotic fractures among Asia-Pacific populations are expected to increase exponentially, due to the region's rapidly aging population, mounting urbanisation, and subsequent increase in sedentary lifestyles. - Osteoporosis is greatly under-diagnosed and under-treated in Asia, even among those at highest risk who have already fractured. In most developing countries of the Asia Pacific, especially in rural areas, DXA technology is not widely available. About World Osteoporosis Day Falling each year on October 20, World Osteoporosis Day raises awareness of bone health and osteoporosis prevention. This year's campaign, under the banner of 'Take Action for Bone Health', calls for global action to fight osteoporosis and related fractures. See: www.worldosteoporosisday.org. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)




















